Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

US Treasury Secretary downplays Russia sanctions waiver, warns Zelensky to 'be careful'

Trump appointee Scott Bessent insisted that no sanctions against Russia had been lifted — they had merely been waived.

US Treasury Secretary downplays Russia sanctions waiver, warns Zelensky to 'be careful'

U.S. Treasury Secretary Scott Bessent dismissed claims that recent U.S. actions were giving Russia an advantage and cautioned President Volodymyr Zelensky to be cautious, according to an NBC News interview on October 18. The remarks followed President Trump waiving most sanctions and tariffs from a bipartisan Russia sanctions bill he signed last month.

Zelensky had previously claimed the recent slowdown in Ukrainian Starlink access was due to American government intervention. Bessent urged Zelensky to verify such assertions, as they were not accurate. Following SpaceX's imposition of a speed cap on Ukraine's Starshield services, speculation arose over whether the restrictions stemmed from SpaceX, the U.S. government, or external sabotage.

The Ukrainian military depends on Starshield services for operations. Concurrently, the U.S. threatened to withdraw intelligence support if Ukraine continued bombing Russian oil refineries. SpaceX CEO Elon Musk reportedly suggested the speed cap to Trump, who reportedly agreed. Zelensky claimed on a previous appearance on NBC's Meet the Press that Ukrainian intelligence indicated U.S. government orders led to the Starlink restriction.

Both Trump and U.S. Secretary of State Marco Rubio denied the accusation, with Bessent calling Zelensky's claim reckless. Bessent also addressed the Trump administration's decision to waive sanctions under the recently enacted Graham Act, stating only the diesel embargo was lifted, and emphasized that no sanctions were ever lifted.

Written by urgent.news from Kyiv Independent's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at kyivindependent.com →

More in Finance & Markets

Where Will CRISPR Therapeutics Stock Be in 2030?

The company's expertise in gene editing could lead to more breakthroughs.

  • CRISPR Therapeutics stock declined 47% since mid-2021 while S&P 500 gained 73%.
  • Received approval for Casgevy, first CRISPR-based gene-editing therapy in 2023.
  • Promising pipeline candidates include LDL cholesterol reducer CTX310 and anticoagulant CTX611.

More from Sunday 18 October →